News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Anand Patel: Our poster (3192) on allo-HCT in MPN-AP/BP in the current era of myeloid therapies at ASH23
Photo taken from Anand Patel/X
Dec 15, 2023, 06:30

Anand Patel: Our poster (3192) on allo-HCT in MPN-AP/BP in the current era of myeloid therapies at ASH23

Quoting Anand Patel, Assistant Professor and Director of the Inpatient Leukemia Service at the University of Chicago, on X/Twitter:

“Our poster (3192) on allogeneic hematopoietic cell transplantation (allo-HCT) in Accelerated Phase of Myeloproliferative Neoplasms/Blast Phase (MPN-AP/BP) in the current era of myeloid therapies at the American Society of Hematology (ASH23).

-65 of 202 patients received allo-HCT.

-Median overall survival 2.3 years from the time of allo-HCT.

-No difference in overall survival based on first-line treatment for MPN-AP/BP or response prior to allo.”

Anand Patel: Our poster (3192) on allo-HCT in MPN-AP/BP in the current era of myeloid therapies at ASH23

Source: Anand Patel/X

allo-HCT American Society of Hematology Anand Patel ASH23 cancer MPN-AP/BP OncoDaily Oncology University of Chicago
Special Coverage
Blog
Feb 22, 2025, 14:43
Giannis Mountzios: How active ADCs against oncogene-addicted NSCLC?
Science
Feb 22, 2025, 14:10
Yan Leyfman: Advancing CAR T-Cell Therapy - Off-the-Shelf Allogeneic Approach
Science
Feb 22, 2025, 13:28
Elvina Almuradova: Immunotherapy for HPV-Associated Cancers
Opinion
Feb 22, 2025, 13:10
Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding
Science
Feb 22, 2025, 13:10
Why immunotherapy has struggled in EGFR+ lung cancer - EGFR Positive Lung Cancer UK
Blog
Feb 22, 2025, 13:04
Debate session on the management of stage III NSCLC in the IO era - ESTRO
Celebrities
Feb 22, 2025, 11:40
Remembering Saxophonist James Casey: His Battle with Colon Cancer and Advocacy
Career
Feb 22, 2025, 11:36
Joseph H. Antin Received ASTCT Lifetime Achievement Award at 2025 Tandem Meetings
Science
Feb 22, 2025, 11:28
Myeloma Paper of the Day, February 22nd, suggested by Robert Orlowski
Blog
Feb 22, 2025, 11:22
Yan Leyfman: Great experience speaking at the NSHSS Pre-Medicine Workshop
Insight
Feb 22, 2025, 11:15
Henrik Ullum: The urgent need to protect WHO is also an opportunity
Oncolibrary
Feb 22, 2025, 11:02
New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer